Key result
Higher serum sclerostin linked to ~4% greater atherosclerotic risk per pmol/L in T2D.
Cross-Sectional (n=78)
Answers are grounded in this paper and cite their sources.
Cross-sectional study shows elevated sclerostin levels in type 2 diabetes patients with atherosclerosis, suggesting Wnt signaling involvement.
OBJECTIVE: Wnt/β-catenin signaling is related to the pathogenesis of several diseases. Sclerostin is an inhibitor of Wnt/β-catenin signaling. However, there are few data regarding the sclerostin levels and vascular disease. Our aim was to examine the relationship between serum sclerostin and atherosclerotic disease (AD) in type 2 diabetes mellitus (T2DM). RESEARCH DESIGN AND METHODS: We performed a cross-sectional study including 78 T2DM patients (45.3% females, mean age 59 ± 5.7 years; 54.7% males, 57.4 ± 6.7 years). RESULTS: Serum sclerostin concentrations of T2DM patients in the AD group were significantly higher than in the non-AD group (P = 0.006). For each increase of 1 pmol/L in sclerostin level, there was a 4% increase of the risk of AD in T2DM patients. A concentration of ≥ 42.3 pmol/L showed a sensitivity of 69% and a specificity of 54.8% to detect an increased risk of AD. In males, sclerostin levels were higher in those with AD (P = 0.04), abnormal intima-media thickness (IMT) (P = 0.004), carotid plaques (P < 0.001), and aortic calcification (P < 0.001). In females, higher levels of sclerostin were related to abnormal IMT (P = 0.03) and aortic calcifications (P = 0.004). Homocysteine (β = 0.319 [95% CI 0.561-2.586], P = 0.003) and IMT (β = 0.330 [14.237-67.693], P = 0.003) were positively correlated with sclerostin. CONCLUSIONS: Circulating sclerostin is increased in T2DM patients with atherosclerotic lesions. Although the sample size of our study was small, these data suggest that sclerostin levels could be a major modulator of Wnt signaling in AD with implications in T2DM patients.
No takes yet. Share an insight, caveat, or question.
Morales et al. (2013) conducted a cross-sectional in Type 2 diabetes mellitus and atherosclerotic disease (n=78). Serum sclerostin levels vs. Lower serum sclerostin levels / Non-atherosclerotic disease was evaluated on Atherosclerotic disease (AD) (4% risk increase per 1 pmol/L, p=0.006). Higher serum sclerostin levels in patients with type 2 diabetes were associated with atherosclerotic disease, increasing risk by 4% per 1 pmol/L increase.
Synapse has enriched 10 related papers. Consider them for comparative context: